Discovery of a Potent Proteolysis Targeting Chimera Enables Targeting the Scaffolding Functions of FK506‐Binding Protein 51 (FKBP51)

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

Extent: Online-Ressource

Language: Englisch

Bibliographic citation: In: Angewandte Chemie International Edition, 63, (3), Wiley-VCH, ISSN 1433-7851

Event: Veröffentlichung

(where): Darmstadt

(who): Universitäts- und Landesbibliothek

(when): 2024

Creator: Geiger, Thomas M.
Walz, Michael
Meyners, Christian
Kuehn, Angela
Dreizler, Johannes
Sugiarto, Wisely O.
Maciel, Edvaldo V. S.
Zheng, Min
Lermyte, Frederik
Hausch, Felix

DOI: 10.26083/tuprints-00027257

URN: urn:nbn:de:tuda-tuprints-272575

Rights: Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 10:49 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Geiger, Thomas M.
Walz, Michael
Meyners, Christian
Kuehn, Angela
Dreizler, Johannes
Sugiarto, Wisely O.
Maciel, Edvaldo V. S.
Zheng, Min
Lermyte, Frederik
Hausch, Felix
Universitäts- und Landesbibliothek

Time of origin

2024

Other Objects (12)

Discovery of a Potent Proteolysis Targeting Chimera Enables Targeting the Scaffolding Functions of FK506‐Binding Protein 51 (FKBP51)

Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy

Proteolysis targeting chimera (PROTAC)-driven antibody internalization of oncogenic cell surface receptors

Development of the first selective proteolysis targeting chimera for the FK506-binding protein 51

Degradation of neurodegenerative disease-associated TDP-43 aggregates and oligomers via a proteolysis-targeting chimera

A proteolysis-targeting chimera molecule selectively degrades ENL and inhibits malignant gene expression and tumor growth

Proteolysis Targeting Chimera (PROTAC) for Macrophage Migration Inhibitory Factor (MIF) Has Anti‐Proliferative Activity in Lung Cancer Cells

Proteolysis targeting chimeras (PROTACs) for epigenetics research

Targeting proteolysis in viral cardiac inflammatory disease

Proteolysis targeting chimeras (PROTACs) in cancer therapy

Proteolysis-targeting chimeras (PROTACs) in cancer therapy

Discovery of a Potent Proteolysis Targeting Chimera Enables Targeting the Scaffolding Functions of FK506‐Binding Protein 51 (FKBP51)

Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy

Proteolysis targeting chimera (PROTAC)-driven antibody internalization of oncogenic cell surface receptors

Development of the first selective proteolysis targeting chimera for the FK506-binding protein 51

Degradation of neurodegenerative disease-associated TDP-43 aggregates and oligomers via a proteolysis-targeting chimera

A proteolysis-targeting chimera molecule selectively degrades ENL and inhibits malignant gene expression and tumor growth

Proteolysis Targeting Chimera (PROTAC) for Macrophage Migration Inhibitory Factor (MIF) Has Anti‐Proliferative Activity in Lung Cancer Cells

Proteolysis targeting chimeras (PROTACs) for epigenetics research

Targeting proteolysis in viral cardiac inflammatory disease

Proteolysis targeting chimeras (PROTACs) in cancer therapy

Proteolysis-targeting chimeras (PROTACs) in cancer therapy

Discovery of a Potent Proteolysis Targeting Chimera Enables Targeting the Scaffolding Functions of FK506‐Binding Protein 51 (FKBP51)

Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy

Proteolysis targeting chimera (PROTAC)-driven antibody internalization of oncogenic cell surface receptors

Development of the first selective proteolysis targeting chimera for the FK506-binding protein 51

Degradation of neurodegenerative disease-associated TDP-43 aggregates and oligomers via a proteolysis-targeting chimera

A proteolysis-targeting chimera molecule selectively degrades ENL and inhibits malignant gene expression and tumor growth

Proteolysis Targeting Chimera (PROTAC) for Macrophage Migration Inhibitory Factor (MIF) Has Anti‐Proliferative Activity in Lung Cancer Cells

Proteolysis targeting chimeras (PROTACs) for epigenetics research

Targeting proteolysis in viral cardiac inflammatory disease

Proteolysis targeting chimeras (PROTACs) in cancer therapy

Proteolysis-targeting chimeras (PROTACs) in cancer therapy

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Discovery of a Potent Proteolysis Targeting Chimera Enables Targeting the Scaffolding Functions of FK506‐Binding Protein 51 (FKBP51)

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Time of origin

Other Objects (12)

Discovery of a Potent Proteolysis Targeting Chimera Enables Targeting the Scaffolding Functions of FK506‐Binding Protein 51 (FKBP51)

Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy

Proteolysis targeting chimera (PROTAC)-driven antibody internalization of oncogenic cell surface receptors

Development of the first selective proteolysis targeting chimera for the FK506-binding protein 51

Degradation of neurodegenerative disease-associated TDP-43 aggregates and oligomers via a proteolysis-targeting chimera

A proteolysis-targeting chimera molecule selectively degrades ENL and inhibits malignant gene expression and tumor growth

Proteolysis Targeting Chimera (PROTAC) for Macrophage Migration Inhibitory Factor (MIF) Has Anti‐Proliferative Activity in Lung Cancer Cells

Proteolysis Targeting Chimera (PROTAC) for Macrophage Migration Inhibitory Factor (MIF) Has Anti‐Proliferative Activity in Lung Cancer Cells

Proteolysis targeting chimeras (PROTACs) for epigenetics research

Targeting proteolysis in viral cardiac inflammatory disease

Proteolysis targeting chimeras (PROTACs) in cancer therapy

Proteolysis-targeting chimeras (PROTACs) in cancer therapy

Discovery of a Potent Proteolysis Targeting Chimera Enables Targeting the Scaffolding Functions of FK506‐Binding Protein 51 (FKBP51)

Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy

Proteolysis targeting chimera (PROTAC)-driven antibody internalization of oncogenic cell surface receptors

Development of the first selective proteolysis targeting chimera for the FK506-binding protein 51

Degradation of neurodegenerative disease-associated TDP-43 aggregates and oligomers via a proteolysis-targeting chimera

A proteolysis-targeting chimera molecule selectively degrades ENL and inhibits malignant gene expression and tumor growth

Proteolysis Targeting Chimera (PROTAC) for Macrophage Migration Inhibitory Factor (MIF) Has Anti‐Proliferative Activity in Lung Cancer Cells

Proteolysis Targeting Chimera (PROTAC) for Macrophage Migration Inhibitory Factor (MIF) Has Anti‐Proliferative Activity in Lung Cancer Cells

Proteolysis targeting chimeras (PROTACs) for epigenetics research

Targeting proteolysis in viral cardiac inflammatory disease

Proteolysis targeting chimeras (PROTACs) in cancer therapy

Proteolysis-targeting chimeras (PROTACs) in cancer therapy

Discovery of a Potent Proteolysis Targeting Chimera Enables Targeting the Scaffolding Functions of FK506‐Binding Protein 51 (FKBP51)

Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy

Proteolysis targeting chimera (PROTAC)-driven antibody internalization of oncogenic cell surface receptors

Development of the first selective proteolysis targeting chimera for the FK506-binding protein 51

Degradation of neurodegenerative disease-associated TDP-43 aggregates and oligomers via a proteolysis-targeting chimera

A proteolysis-targeting chimera molecule selectively degrades ENL and inhibits malignant gene expression and tumor growth

Proteolysis Targeting Chimera (PROTAC) for Macrophage Migration Inhibitory Factor (MIF) Has Anti‐Proliferative Activity in Lung Cancer Cells

Proteolysis Targeting Chimera (PROTAC) for Macrophage Migration Inhibitory Factor (MIF) Has Anti‐Proliferative Activity in Lung Cancer Cells

Proteolysis targeting chimeras (PROTACs) for epigenetics research

Targeting proteolysis in viral cardiac inflammatory disease

Proteolysis targeting chimeras (PROTACs) in cancer therapy

Proteolysis-targeting chimeras (PROTACs) in cancer therapy

Related objects

Reset password